Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

BACKGROUND: Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models. However, in immune-desert models, the efficacy of YM101 was limited. Bivalent manganese (Mn(2+)) is identified as a natural stimulator...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Ming, Niu, Mengke, Zhang, Jing, Li, Shiyu, Zhu, Shuangli, Yan, Yongxiang, Li, Ning, Zhou, Pengfei, Chu, Qian, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442312/
https://www.ncbi.nlm.nih.gov/pubmed/34526097
http://dx.doi.org/10.1186/s13045-021-01155-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442312/
https://www.ncbi.nlm.nih.gov/pubmed/34526097
http://dx.doi.org/10.1186/s13045-021-01155-6

Ejemplares similares